These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Carboplatin. Med Lett Drugs Ther; 1989 Sep; 31(800):83-4. PubMed ID: 2671623 [No Abstract] [Full Text] [Related]
3. Carboplatin versus cisplatin. Tighe M; Goodman S Lancet; 1988 Dec; 2(8624):1372-3. PubMed ID: 2904096 [No Abstract] [Full Text] [Related]
4. Carboplatin substitution for cisplatin in the treatment of ovarian carcinoma--a word of caution. McGuire WP; Abeloff MD J Natl Cancer Inst; 1989 Oct; 81(19):1438-9. PubMed ID: 2674458 [No Abstract] [Full Text] [Related]
5. Comparing cisplatin and carboplatin. Neijt JP; van Houwelingen JC J Natl Cancer Inst; 1990 Mar; 82(5):434-5. PubMed ID: 2406453 [No Abstract] [Full Text] [Related]
6. Treating ovarian cancer. Sweetenham JW; Mead GM; Whitehouse JM; Williams CJ Br Med J (Clin Res Ed); 1986 Nov; 293(6559):1435-6. PubMed ID: 3099901 [No Abstract] [Full Text] [Related]
8. High-dose platinum consisting of combined carboplatin and cisplatin in previously untreated ovarian cancer patients with residual disease. Lund B; Hansen M; Hansen OP; Hansen HH J Clin Oncol; 1989 Oct; 7(10):1469-73. PubMed ID: 2674334 [TBL] [Abstract][Full Text] [Related]
9. Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds. Gore ME; Fryatt I; Wiltshaw E; Dawson T Gynecol Oncol; 1990 Feb; 36(2):207-11. PubMed ID: 2404837 [TBL] [Abstract][Full Text] [Related]
11. Evaluation of platinum-DNA adduct levels relative to known prognostic variables in a cohort of ovarian cancer patients. Reed E; Ostchega Y; Steinberg SM; Yuspa SH; Young RC; Ozols RF; Poirier MC Cancer Res; 1990 Apr; 50(8):2256-60. PubMed ID: 2180564 [TBL] [Abstract][Full Text] [Related]
12. Second-line treatment of advanced measurable ovarian cancer with iproplatin: a Southwest Oncology Group study. Weiss G; Green S; Alberts DS; Thigpen JT; Hines HE; Hanson K; Pierce HI; Baker LH; Goodwin JW Eur J Cancer; 1991; 27(2):135-8. PubMed ID: 1827275 [TBL] [Abstract][Full Text] [Related]
14. "Recurrence within 6 months of platinum therapy": an adequate definition of "platinum-refractory" ovarian cancer? Markman M Gynecol Oncol; 1998 May; 69(2):91-2. PubMed ID: 9600812 [No Abstract] [Full Text] [Related]
15. Intraperitoneal carboplatin: favorable results in women with minimal residual ovarian cancer after cisplatin therapy. Speyer JL; Beller U; Colombo N; Sorich J; Wernz JC; Hochster H; Green M; Porges R; Muggia FM; Canetta R J Clin Oncol; 1990 Aug; 8(8):1335-41. PubMed ID: 2199620 [TBL] [Abstract][Full Text] [Related]
16. [Ovarian cancer--therapeutic options after the failure of the first line of treatment]. Jabłońska E; Chłosta M; Pawlega J Ginekol Pol; 2004 Jan; 75(1):58-64. PubMed ID: 15112475 [TBL] [Abstract][Full Text] [Related]
17. CA125 in ovarian tumour tissue at second laparotomy. Maughan TS; Fish RG; Shelley MD; Jasani B; Williams GT; Adams M Br J Cancer; 1989 Feb; 59(2):259-60. PubMed ID: 2649131 [No Abstract] [Full Text] [Related]
18. New drugs and experimental approaches in ovarian cancer treatment. Thigpen JT; Vance RB; Balducci L; Khansur T Semin Oncol; 1984 Sep; 11(3):314-26. PubMed ID: 6435251 [No Abstract] [Full Text] [Related]
19. Carboplatin in the first-line chemotherapy of ovarian cancer. Alberts DS; Canetta R; Mason-Liddil N Semin Oncol; 1990 Feb; 17(1 Suppl 2):54-60. PubMed ID: 2406922 [TBL] [Abstract][Full Text] [Related]
20. Continued chemosensitivity to cisplatin/carboplatin in ovarian carcinoma despite treatment with multiple prior platinum-based regimens. Markman M; Kennedy A; Webster K; Kulp B; Peterson G; Belinson J Gynecol Oncol; 1997 Jun; 65(3):434-6. PubMed ID: 9190971 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]